Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

11.36 +0.22 (+2.02%)
Streaming Delayed Price Updated: 3:27 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
AI: The Great Disruptor or the Great Divider? ↗
Via Chartmill
News headline image
NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside ↗
H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax. 
Via Stocktwits
Topics Government
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Novocure Stock Surges Nearly 30% After Hours: FDA Clears First New Pancreatic Cancer Therapy In Almost Three Decades ↗
The stock is on track to record its best day since December 2024 if the overnight gains hold. 
Via Stocktwits
News headline image
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novocure (NVCR) Q2 2025 Earnings Call Transcript ↗
Novocure (NVCR) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q3 2025 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
News headline image
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon ↗
If you have decades of investing runway left, consider these two top healthcare stocks. 
Via The Motley Fool
News headline image
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher ↗
Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers. 
Via Chartmill
News headline image
Novocure Reports Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
From Novocure
Via Business Wire
News headline image
Novocure to Report Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
From Novocure
Via Business Wire
News headline image
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
From Novocure
Via Business Wire
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.